| $350M | ||
| $217M | ||
| $109M | ||
| $107M | ||
| $104M | ||
| $100M |
Buys | $172,499,918 | 1 | 2 |
Sells | $507,965,998 | 58 | 98 |
| BAKER BROS. ADVISORS LP | 1 | $172.5M | 0 | $0 | $172.5M | |
| Albers Jeffrey W. | director | 0 | $0 | 1 | $448,823 | $-448,823 |
| Adams Brian | Chief Legal Officer | 0 | $0 | 1 | $744,297 | $-744,297 |
| Ridloff Elena | director | 0 | $0 | 3 | $1.29M | $-1.29M |
| Goodman Noah | Chief Business Officer | 0 | $0 | 6 | $2.22M | $-2.22M |
| Esposito Pamela | director | 0 | $0 | 4 | $3.05M | $-3.05M |
| Gollob Jared | Chief Medical Officer | 0 | $0 | 3 | $5.29M | $-5.29M |
| Jacobs Bruce N. | Chief Financial Officer | 0 | $0 | 3 | $9.96M | $-9.96M |
| Chadwick Jeremy G | Chief Operating Officer | 0 | $0 | 12 | $15.6M | $-15.6M |
| Mainolfi Nello | Chief Executive Officer | 0 | $0 | 7 | $34.99M | $-34.99M |
| BVF PARTNERS L P/IL | See Remarks and Footnotes | 0 | $0 | 1 | $173.67M | $-173.67M |
| Booth Bruce | director | 0 | $0 | 17 | $260.71M | $-260.71M |
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized …
Over the last 12 months, insiders at Kymera Therapeutics, Inc. have bought $172.5M and sold $507.97M worth of Kymera Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Kymera Therapeutics, Inc. have bought $47.89M and sold $129.63M worth of stock each year.
Highest buying activity among insiders over the last 12 months: BAKER BROS. ADVISORS LP () — $172.5M.
The last purchase of 2,005,813 shares for transaction amount of $172.5M was made by BAKER BROS. ADVISORS LP () on 2025‑12‑11.
| 2026-10-01 | Sale | Mainolfi Nello | Chief Executive Officer | 30,000 0.0377% | $113.80 | $3.41M | +0.66% | |
| 2026-09-04 | Sale | Adams Brian | Chief Legal Officer | 6,371 0.0077% | $116.83 | $744,297 | -3.61% | |
| 2026-07-07 | Sale | Mainolfi Nello | Chief Executive Officer | 50,000 0.063% | $119.00 | $5.95M | -4.39% | |
| 2026-07-01 | Sale | Mainolfi Nello | Chief Executive Officer | 80,000 0.0982% | $115.29 | $9.22M | -0.15% | |
| 2026-07-01 | Sale | Goodman Noah | Chief Business Officer | 3,389 0.0041% | $114.29 | $387,329 | -0.15% | |
| 2026-06-30 | Sale | Jacobs Bruce N. | Chief Financial Officer | 77,109 0.094% | $114.96 | $8.86M | -0.52% | |
| 2026-06-29 | Sale | Booth Bruce | director | 75,442 0.0906% | $108.01 | $8.15M | +4.39% | |
| 2026-06-29 | Sale | Booth Bruce | director | 76,650 0.0921% | $108.05 | $8.28M | +4.39% | |
| 2026-06-26 | Sale | Booth Bruce | director | 467,878 0.5802% | $110.29 | $51.6M | +5.51% | |
| 2026-06-26 | Sale | BVF PARTNERS L P/IL | See Remarks and Footnotes | 1.63M 1.8128% | $106.50 | $173.67M | +5.51% | |
| 2026-06-25 | Sale | Booth Bruce | director | 548,321 0.8057% | $118.76 | $65.12M | -2.09% | |
| 2026-06-25 | Sale | Booth Bruce | director | 285,684 0.3634% | $121.86 | $34.81M | -2.09% | |
| 2026-06-25 | Sale | Goodman Noah | Chief Business Officer | 5,000 0.0071% | $114.00 | $570,000 | -2.09% | |
| 2026-06-24 | Sale | Booth Bruce | director | 134,720 0.1675% | $100.51 | $13.54M | +14.22% | |
| 2026-06-23 | Sale | Booth Bruce | director | 1,408 0.0017% | $99.98 | $140,772 | +16.06% | |
| 2026-06-22 | Sale | Booth Bruce | director | 278,128 0.3706% | $99.12 | $27.57M | +14.64% | |
| 2026-06-22 | Sale | Goodman Noah | Chief Business Officer | 2,500 0.0033% | $99.00 | $247,500 | +14.64% | |
| 2026-06-18 | Sale | Booth Bruce | director | 115,056 0.1408% | $91.01 | $10.47M | +26.05% | |
| 2026-06-17 | Sale | Booth Bruce | director | 116,812 0.1427% | $90.34 | $10.55M | +26.53% | |
| 2026-05-27 | Sale | Chadwick Jeremy G | Chief Operating Officer | 4,279 0.0052% | $81.58 | $349,096 | +37.18% |
| BAKER BROS. ADVISORS LP | 7955916 9.3192% | $1.01B | 3 | 0 | +30.12% | |
| BVF PARTNERS L P/IL | See Remarks and Footnotes | 78787 0.0923% | $10.01M | 9 | 1 | +32.33% |
| LAMPERT MARK N | 257754 0.3019% | $32.76M | 4 | 0 | +55.87% |
$961,890,236 | 276 | 22.46% | $23.97B | |
$159,914,414 | 243 | 18.52% | $8.86B | |
$273,531,368 | 93 | 38.24% | $9.16B | |
$2,765,836 | 72 | 20.00% | $10.77B | |
$108,876,545 | 67 | 72.81% | $14.6B |
| Increased Positions | 165 | +78.95% | 14M | +17.72% |
| Decreased Positions | 92 | -44.02% | 5M | -6.67% |
| New Positions | 68 | New | 2M | New |
| Sold Out Positions | 21 | Sold Out | 421,479 | Sold Out |
| Total Postitions | 282 | +34.93% | 90M | +11.05% |
| Baker Bros. Advisors Lp | $483,958.00 | 8.42% | 6.65M | 0 | 0% | 2025-09-30 |
| Avoro Capital Advisors Llc | $462,026.00 | 8.04% | 6.35M | -205,555 | -3.14% | 2025-09-30 |
| Fmr Llc | $427,800.00 | 7.44% | 5.88M | +447,617 | +8.24% | 2025-09-30 |
| Bvf Inc/Il | $400,377.00 | 6.97% | 5.5M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $394,484.00 | 6.86% | 5.42M | -198,126 | -3.52% | 2025-09-30 |
| Wellington Management Group Llp | $378,038.00 | 6.58% | 5.2M | -176,370 | -3.28% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $370,885.00 | 6.45% | 5.1M | -2M | -25.69% | 2025-09-30 |
| Atlas Venture Life Science Advisors, Llc | $356,267.00 | 6.2% | 4.9M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $317,630.00 | 5.53% | 4.37M | +217,188 | +5.24% | 2025-09-30 |
| Siren, L.L.C. | $249,432.00 | 4.34% | 3.43M | 0 | 0% | 2025-09-30 |